Last reviewed · How we verify
NCT04028310: DDMR
Developmental Dyslexia and Remediation Methods
NA trial testing Phonological in Dyslexia, Developmental in 145 participants. Completed in 12 December 2022.
12 December 2022
Quick facts
| Lead sponsor | Fondation Lenval |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | other |
| Enrollment | 145 |
| Start date | 25 October 2019 |
| Primary completion | 12 December 2022 |
| Estimated completion | 12 December 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Phonological
- Visual-attention
Conditions studied
- Dyslexia, Developmental — all drugs for Dyslexia, Developmental →
Sponsor
Fondation Lenval — full company profile →
Who can join
Adults 8 to 13, any sex, with Dyslexia, Developmental. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At least, three theoretical frameworks are currently involved in therapeutic research in developmental dyslexia. Each theoretical framework relies on the type of underlying cognitive processes that is viewed as impaired: 1°) phonological processing, 2°) cross modal integration, 3°) visual attention processing. In this controlled and randomized study, three types of computerized training are combined in a multi-factorial remedial approach in 8 to 12 year old children with dyslexia. The main objective is to compare the effectiveness of this remedial approach which combines phonological, visual-attentional and cross-modal training with conventional non-intensive and non-specific rehabilitation
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Multimodal intervention in 8- to 13-year-old French dyslexic readers: Study protocol for a randomized multicenter controlled crossover trial.
Harrar-Eskinazi KL, De Cara B, Leloup G, Nothelier J, et al · · 2022 · cited 2× · PMID 36578007 · DOI 10.1186/s12887-022-03701-8 -
Effects of a developmental dyslexia remediation protocol based on the training of audio-phonological cognitive processes in dyslexic children with high intellectual potential: study protocol for a multiple-baseline single-case experimental design.
Darrot G, Gros A, Manera V, De Cara B, et al · · 2023 · PMID 37592217 · DOI 10.1186/s12887-023-04189-6
Verify or expand the search:
- PubMed search for NCT04028310
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fondation Lenval trials
Trials by the same sponsor.
- NCT06968546 — Sufentanil Versus Ketamine Intranasally in the Management of Severe Acute Trauma-related Pain in Children. · Phase 2 · not yet recruiting
- NCT07383844 — Analysis of Barriers and Facilitators to Adapted Physical Activity for Pediatric Patients With Chronic Inflammatory Bowe · recruiting
- NCT07299006 — Evaluation of Paro, a Therapeutic Assistance Robot in Analgesic Management During the Placement of a Peripheral Intraven · NA · not yet recruiting
- NCT07068945 — Study of the Transition From Child Psychiatry to Adult Psychiatry in Nice Within a Population of 17-year-old Adolescents · not yet recruiting
- NCT06231654 — Evaluation of Remote Photoplethysmography to Assist Vital Signs Measure in Pediatrics · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04028310 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondation Lenval
- Last refreshed: 29 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04028310.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing